

Alessandro Nini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615941/publications.pdf>

Version: 2024-02-01

85
papers

1,199
citations

471061

17
h-index

395343

33
g-index

105
all docs

105
docs citations

105
times ranked

2055
citing authors

#	ARTICLE	IF	CITATIONS
1	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. <i>European Urology</i> , 2015, 67, 212-219.	0.9	178
2	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2012, 61, 1132-1138.	0.9	120
3	Tbr2-positive intermediate (basal) neuronal progenitors safeguard cerebral cortex expansion by controlling amplification of pallial glutamatergic neurons and attraction of subpallial GABAergic interneurons. <i>Genes and Development</i> , 2010, 24, 1816-1826.	2.7	94
4	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 546-551.	0.9	81
5	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74
6	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. <i>European Urology</i> , 2016, 69, 1142-1148.	0.9	60
7	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. <i>European Urology</i> , 2015, 68, 777-784.	0.9	48
8	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. <i>European Urology Oncology</i> , 2020, 3, 209-215.	2.6	37
9	On-clamp versus off-clamp partial nephrectomy: Propensity score-matched comparison of long-term functional outcomes. <i>International Journal of Urology</i> , 2019, 26, 985-991.	0.5	36
10	Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. <i>Acta Diabetologica</i> , 2014, 51, 801-811.	1.2	33
11	Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. <i>European Urology Focus</i> , 2016, 1, 272-281.	1.6	33
12	Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. <i>European Urology</i> , 2018, 73, 793-799.	0.9	33
13	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.2	32
14	Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy—Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?. <i>Journal of Urology</i> , 2018, 200, 1030-1034.	0.2	25
15	Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. <i>Frontiers in Surgery</i> , 2018, 5, 80.	0.6	24
16	Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. <i>Current Medical Research and Opinion</i> , 2014, 30, 719-732.	0.9	20
17	Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. <i>World Journal of Urology</i> , 2016, 34, 1139-1145.	1.2	19
18	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. <i>Radiotherapy and Oncology</i> , 2013, 109, 211-216.	0.3	18

#	ARTICLE	IF	CITATIONS
19	Treatment of Lymph Node-Positive Prostate Cancer: Teaching Old Dogmas New Tricks. <i>European Urology</i> , 2014, 65, 26-28.	0.9	17
20	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
21	Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome. <i>Urologic Clinics of North America</i> , 2019, 46, 419-427.	0.8	14
22	Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. <i>Journal of Urology</i> , 2020, 204, 1242-1248.	0.2	14
23	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012, 4, 347-365.	0.9	12
24	Penile Rehabilitation with Phosphodiesterase Type 5 Inhibitors After Nerve-sparing Radical Prostatectomy: Are We Targeting the Right Patients?. <i>European Urology</i> , 2014, 65, 673-674.	0.9	12
25	The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Frontiers in Surgery</i> , 2018, 5, 26.	0.6	12
26	When to perform preoperative chest computed tomography for renal cancer staging. <i>BJU International</i> , 2017, 120, 490-496.	1.3	11
27	Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. <i>International Journal of Impotence Research</i> , 2014, 26, 201-204.	1.0	10
28	Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 82.e1-82.e5.	0.8	10
29	The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 293.e25-293.e30.	0.8	10
30	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 355-367.	0.7	10
31	Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion. <i>Urologia Internationalis</i> , 2018, 101, 224-231.	0.6	8
32	Retroperitoneal lymph node dissection in the setting of elevated markers. <i>Current Opinion in Urology</i> , 2018, 28, 435-439.	0.9	7
33	The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1623-1629.	1.2	7
34	Pathological High-risk Renal Cell Carcinoma: Trends in Clinical Characteristics Over 25 Years. <i>Anticancer Research</i> , 2018, 38, 4123-4130.	0.5	6
35	Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management. <i>Journal of Urology</i> , 2021, 206, 88-96.	0.2	6
36	Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND). <i>World Journal of Urology</i> , 2022, 40, 349-354.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. <i>World Journal of Urology</i> , 2019, 37, 2081-2090.	1.2	5
38	Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?. <i>World Journal of Urology</i> , 2021, 39, 3231-3237.	1.2	5
39	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. <i>BJU International</i> , 2015, 116, 366-372.	1.3	4
40	Metabolic Syndrome as a Marker for Prostate Cancer: Still a Work in Progress. <i>European Urology</i> , 2015, 67, 71-72.	0.9	4
41	Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 701-708.	1.2	4
42	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
43	Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study. <i>European Urology</i> , 2018, 73, 482-484.	0.9	3
44	Evaluation of the oncologic benefit of adjunctive surgery at time of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).. <i>Journal of Clinical Oncology</i> , 2020, 38, 388-388.	0.8	3
45	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urology and Nephrology</i> , 2020, , .	1.3	3
46	Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.. <i>Journal of Clinical Oncology</i> , 2019, 37, 524-524.	0.8	2
47	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	2
48	Multiparametric-MRI/ultrasound fusion prostate biopsy: Are two biopsy cores per MRI-lesion required?. <i>European Urology Supplements</i> , 2018, 17, e711.	0.1	1
49	Vascular occlusion to protect against intraoperative blood loss in liver surgeries: new perspectives on a traditional technique. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 567-569.	0.7	1
50	MP80-03â€¢fPROGNOSTIC DIFFERENCES AND SURVIVAL OUTCOMES IN PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA SUBTYPES &NDASH; A COMPARISON BETWEEN TYPE I VS. TYPE II. <i>Journal of Urology</i> , 2020, 203, .	0.2	1
51	Clinical and pathological characteristics of a series of patients with newly diagnosed primary renal liposarcoma: natural history and effect on survival. <i>Archivos Espanoles De Urologia</i> , 2018, 71, 555-558.	0.1	1
52	MP22-14 PREOPERATIVE HAEMATOLOGICAL PARAMETERS AS PREDICTORS OF LONG-TERM SURVIVAL IN RENAL CELL&CARCINOMA. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
53	PD24-03 ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
54	MP49-08 ON-CLAMP VERSUS OFF-CLAMP PARTIAL NEPHECTOMY: PROPENSITY SCORE MATCHED COMPARISON OF LONG TERM FUNCTIONAL OUTCOMES. <i>Journal of Urology</i> , 2017, 197, .	0.2	0

#	ARTICLE	IF	CITATIONS
55	MP55-12 LONG-TERM ASSESSMENT OF MORTALITY PATTERNS AFTER SURGICAL TREATMENT FOR NON-METASTATIC KIDNEY CANCER: A COMPETING RISK ANALYSIS. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
56	PD59-08 PROPOSAL AND VALIDATION OF A DYNAMIC CRITERION FOR PATIENT INCLUSION IN KIDNEY CANCER ACTIVE SURVEILLANCE PROTOCOLS. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
57	MP55-15 IMPACT OF INTRAOPERATIVE BLOOD TRANSFUSIONS ON SURVIVAL AFTER SURGERY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
58	PD04-04 THE EFFECT OF ANATOMICAL LOCATION OF RETROPERITONEAL LYMPH NODE METASTASES ON CANCER SPECIFIC SURVIVAL IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
59	MP48-16 ON-CLAMP VERSUS OFF-CLAMP PARTIAL NEPHRECTOMY: PROPENSITY SCORE MATCHED COMPARISON OF LONG TERM FUNCTIONAL OUTCOMES.. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
60	PD23-05 MULTIPARAMETRIC-MRI/ULTRASOUND FUSION PROSTATE BIOPSY: ARE TWO BIOPSY CORES PER MRI-LESION REQUIRED?. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
61	MP62-15 SAFETY OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) IN PATIENTS WITH ANTITHROMBOTIC AGENTS. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
62	Adjunctive surgery in postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) - is there always an oncologic benefit?. <i>European Urology Open Science</i> , 2020, 19, e411.	0.2	0
63	What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? Results from a large, multi-institutional series. <i>European Urology Open Science</i> , 2020, 19, e1212-e1213.	0.2	0
64	Assessing the association between the template of pelvic salvage lymph node dissection for node-only recurrent prostate cancer and oncological outcomes. Results of a multi-institutional series. <i>European Urology</i> , 2021, 79, S1681-S1682.	0.9	0
65	Identifying the optimal candidates for radiation therapy after salvage lymph node dissection for node-only recurrent prostate cancer after radical prostatectomy: Results from a multi-institutional collaboration. <i>European Urology</i> , 2021, 79, S1685-S1686.	0.9	0
66	MP45-08 ACTIVE SURVEILLANCE FOR SMALL RENAL MASSES: A PROSPECTIVE NON-RANDOMIZED MULTIINSTITUTIONAL STUDY (NCT03804320). <i>Journal of Urology</i> , 2021, 206, .	0.2	0
67	MP45-02 EXTERNAL VALIDATION AND HEAD-TO-HEAD COMPARISON OF ALL THE PROGNOSTIC MODELS RECOMMENDED BY THE EUROPEAN ASSOCIATION OF UROLOGY GUIDELINES TO PREDICT ONCOLOGIC OUTCOMES IN PATIENTS WITH RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
68	MP36-16 THE ROLE OF HISTOLOGIC SUBTYPES IN FOLLOW-UP SCHEME OF POSTSURGICAL KIDNEY CANCER PATIENTS. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
69	PD24-12 COMPARISON BETWEEN LIVER DEROTATION WITH PRINGLE MANOEUVRE AND CARDIOPULMONARY BYPASS WITH DEEP-HYPOTHERMIC CARDIAC ARREST FOR KIDNEY CANCER WITH MAYO III TUMOR THROMBUS: INTRA-, PERI- AND POSTOPERATIVE OUTCOMES. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
70	MP53-17 WHERE DO WE MISS EXTRACAPSULAR EXTENSION AT MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE?. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
71	MP53-18 PROPOSAL OF A NOVEL RISK SCORE TO IDENTIFY BIOPSY NAÏVE MEN WITH ELEVATED PSA WHO SHOULD BE CONSIDERED FOR A MULTI- PARAMETRIC MRI. <i>Journal of Urology</i> , 2018, 199, .	0.2	0
72	PD16-06 A NEW PROPOSAL TO IMPROVE THE SURVEILLANCE OF RENAL CELL CARCINOMA PATIENTS AFTER SURGERY. <i>Journal of Urology</i> , 2018, 199, .	0.2	0

#	ARTICLE	IF	CITATIONS
73	MP52-08 ONCOLOGICAL OUTCOMES, SURGICAL SAFETY AND COMPLICATIONS OF PATIENTS TREATED WITH SPOT SPECIFIC SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE. Journal of Urology, 2018, 199, .	0.2	0
74	PD38-04 PATIENTS ADHERING TO STANDARDIZED PROTOCOLS FOR FUNCTIONAL OUTCOME ASSESSMENT AFTER RADICAL PROSTATECTOMY SHOW HIGHER RATES OF RETURN TO PRE-OPERATIVE STATUS: IMPLICATIONS FOR POSSIBLE SELECTION BIASES. Journal of Urology, 2018, 199, .	0.2	0
75	MP73-01 TEMPLATE VERSUS BILATERAL POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH TESTICULAR CANCER. Journal of Urology, 2019, 201, .	0.2	0
76	PD17-08 COMPARING THE DIAGNOSTIC ACCURACY OF 68GA-PSMA AND 11C-CHOLINE PET/CTSCAN ACCORDING TO PSA LEVEL: A LARGE MULTI-INSTITUTIONAL ANALYSIS WITH HISTOLOGICAL VERIFICATION IN PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER. Journal of Urology, 2019, 201, .	0.2	0
77	MP22-03 LONG-TERM ONCOLOGIC OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2019, 201, .	0.2	0
78	Analysis of three models to predict pathohistology in patients undergoing postchemotherapy RPLND for (pcRPLND) advanced nonseminomatous germ cell tumors (NSGCT).. Journal of Clinical Oncology, 2019, 37, e16053-e16053.	0.8	0
79	Validation of the two best models to predict "benign" pathohistology in patients with advanced nonseminomatous germ cell tumors (NSGCT) undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).. Journal of Clinical Oncology, 2020, 38, 389-389.	0.8	0
80	PD49-08 HYPERTENSION AND CARDIOVASCULAR MORBIDITY FOLLOWING RADICAL NEPHRECTOMY ARE ONLY SUSTAINED BY RENAL PARENCHYMA LOSS AND CARDIOVASCULAR MORBIDITY. Journal of Urology, 2020, 203, .	0.2	0
81	MP79-02 PERFORMANCE CHARACTERISTICS OF PET/CT SCAN IN MEN TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR RECURRENT PROSTATE CANCER: A PER PATIENT ANALYSIS WITH PATHOLOGICAL CONFIRMATION ACCORDING TO EACH AREA OF DISSECTION. Journal of Urology, 2020, 203, .	0.2	0
82	Reply by Authors. Journal of Urology, 2020, 204, 302-302.	0.2	0
83	MP76-05 VALIDATION OF THE BEST MODELS TO PREDICT PATHOHISTOLOGY IN GERM CELL TUMOR PATIENTS UNDERGOING POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION. Journal of Urology, 2020, 203, .	0.2	0
84	MP76-04 PREOPERATIVE CLINICAL AND RADIOGRAPHIC PREDICTORS OF MAJOR VASCULAR RECONSTRUCTIONS IN PATIENTS WITH TESTICULAR CANCER UNDERGOING POSTCHEMOTHERAPY RESIDUAL TUMOR RESECTION (PC-RPLND). Journal of Urology, 2020, 203, .	0.2	0
85	MP68-17 MANAGEMENT OF PATIENTS DIAGNOSED WITH ANGIOMYOLIPOMA ACCORDING TO EAU GUIDELINES: PROFILE OF SURGICAL ADVERSE EVENTS TO AID CLINICAL DECISION MAKING. Journal of Urology, 2020, 203, .	0.2	0